Chemours director buys 6,000 shares of stock
Chemours Co director Mary B. Cranston purchased 6,000 shares of Chemours common stock in an open-market transaction on 2026-08-07 at a price of $15.825 per share.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Chemours Co director Mary B. Cranston purchased 6,000 shares of Chemours common stock in an open-market transaction on 2026-08-07 at a price of $15.825 per share. Following this purchase, she reports beneficial ownership of 113,140.9469 shares, which includes directly owned shares, restricted stock units, and dividend equivalent units.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Common Stock F1 | 6,000 | $15.825 | $95K |
Footnotes (1)
- F1. Includes directly owned shares, restricted stock units and dividend equivalent units.
Key Figures
Key Terms
restricted stock units financial
dividend equivalent units financial
beneficial ownership financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Chemours Co (CC) disclose for Mary B. Cranston?
Was the Chemours Co (CC) insider trade by Mary B. Cranston a purchase or a sale?
Does the Chemours Co (CC) Form 4 mention any derivative or option exercises by Mary B. Cranston?
AI-generated analysis. How Rhea-AI works. Not financial advice.